Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
9.085(c) 9.1(c) 9.225(c) 9.37(c) 9.66(c) Last
7 000 605 5 347 783 7 116 527 5 409 962 19 984 455 Volume
-1.46% +0.17% +1.37% +1.57% +3.09% Change
More quotes
Financials (USD)
Sales 2020 4,05 M - -
Net income 2020 -181 M - -
Net Debt 2020 - - -
P/E ratio 2020 -8,20x
Yield 2020 -
Sales 2021 86,4 M - -
Net income 2021 -156 M - -
Net Debt 2021 - - -
P/E ratio 2021 -10,8x
Yield 2021 -
Capitalization 1 636 M 1 636 M -
Capi. / Sales 2020 404x
Capi. / Sales 2021 18,9x
Nbr of Employees 190
Free-Float 97,8%
More Financials
Company
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target... 
More about the company
Notations Surperformance© of Inovio Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about INOVIO PHARMACEUTICALS, INC.
01/06INOVIO PHARMACEUTICALS : Reports Positive Efficacy in Phase 2 Trial of VGX-3100 ..
MT
01/06INOVIO PHARMACEUTICALS : VGX-3100 Demonstrates Positive Phase 2 Efficacy In Trea..
PR
01/04INOVIO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regul..
AQ
01/04Inovio expects to begin late-stage COVID-19 vaccine study in second quarter
RE
01/04INOVIO PHARMACEUTICALS : Partners With Advaccine to Commercialize COVID-19 DNA V..
MT
01/04INOVIO PHARMACEUTICALS : partners with Advaccine to commercialize COVID-19 vacci..
RE
01/04INOVIO PHARMACEUTICALS : and Advaccine Announce Exclusive Partnership To Commerc..
PR
2020SECTOR UPDATE : Health Care Stocks Hang On For Modest Gains
MT
2020INOVIO PHARMACEUTICALS' : Early Stage US Study Shows Potential of COVID-19 Vacci..
MT
2020INOVIO PHARMACEUTICALS : Announces Publication of Phase 1 Data from its COVID-19..
PR
2020INOVIO PHARMACEUTICALS : Wins $38 Million Grant to Develop Antibody Technologies..
MT
2020INOVIO PHARMACEUTICALS : to Develop DNA-encoded Monoclonal Antibody (dMAb®) Cand..
PR
2020Inovio Begins Dosing in Trial of COVID-19 DNA Vaccine Candidate in China
MT
2020INOVIO PHARMACEUTICALS : and Advaccine Announce First Dosing of Subject in Phase..
PR
2020Inovio Pharmaceuticals Reports Positive Efficacy Results From Phase 2 Trial o..
MT
More news
News in other languages on INOVIO PHARMACEUTICALS, INC.
2020WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2020Wall Street, lestée par la tech, finit dans le rouge
2020BioNTech treibt Corona-Impfstoffprojekt nach positiven Daten voran
2020WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2020WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Stock Trading Strategies
INOVIO PHARMACEUTICALS, INC. - 2020
Close to a key resistance level
BUY
More Stock Trading Analysis
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 12,29 $
Last Close Price 9,66 $
Spread / Highest target 107%
Spread / Average Target 27,2%
Spread / Lowest Target -17,2%
EPS Revisions
Managers and Directors
NameTitle
J. Joseph Kim President, Chief Executive Officer & Director
Simon X. Benito Chairman
Jacqueline E. Shea Chief Operating Officer & Executive Vice President
Peter D. Kies Chief Financial & Accounting Officer
Laurent M. Humeau Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
INOVIO PHARMACEUTICALS, INC.9.15%1 636
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-12.53%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601